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Chelation therapy has long been regarded as
a suitable approach to the therapeutic and
even prophylactic removal of potentially
toxic metals from body tissues. And there
have been apparent successes in some areas,
but there are also needs for a better under-
standing of the underlying pharmacology
and for the development ofsafer and more
effective agents.
There are currently three areas of inter-
est in the clinical use of chelating drugs:
treatment of heavy metal toxicity, removal
of metals accumulated in body tissues
because of genetic disorders, and chelation
therapy of degenerative diseases of the
blood vessels. An NIEHS symposium
focused primarily on mechanisms, effective-
ness, and potential adverse effects of tradi-
tional as well as new chelating agents (see
Meeting Report in this issue). While most
ofthe presentations concerned treatment of
low-level lead exposures, the conference
topics and discussions extended into the
current status ofchelation therapy for other
disorders. There were also discussions of
rationales for designing appropriate chelat-
ing agents. Experimental results ofthe labo-
ratory testing of promising new drugs sug-
gest that the development of more specific
and effective agents is possible. None ofthe
new drugs have been subjected to human
clinical trials.
Much of the current interest in chelat-
ing agents stems from concerns about the
possible beneficial effects of removal of
toxic metals in people with low-level expo-
sures without overt symptoms of toxicity.
This interest is prompted by emerging evi-
dence that toxic effects from exposures to
lead, cadmium, and mercury may occur at
levels previously thought to be harmless and
at levels that do not produce overt clinical
symptoms. It is now well established that
low-level exposures to lead in early child-
hood may impair cognitive and behavioral
development (1), while lifetime accumula-
tions of cadmium in liver and kidney are
associated with renal tubular dysfunction
and hypercalciuria in later life (2). More
recently, there have been assertions that
mercury vapor released from dental amal-
gams might be responsible for a spectrum
ofchronic health problems (3,4). Although
it may be debated as to what the lowest lev-
els for concern might be for each of these
metals, it is clear that the margin between
the levels of exposure for persons living in
the industrialized nations of the world and
levels of exposure currently recognized as
producing the lowest adverse effect levels is
small. While efforts to reduce exposure to
these metals are being implemented, there
are large populations ofchildren and adults
that might have exposures that exceed rec-
ommended levels or have some slight,
though measurable, adverse effect.
In spite of the substantial decline in
blood lead levels (BPb) for children in the
United States over the last 10 years as
determined by the most recent National
Health and Nutrition Evaluation Survey,
35% ofnon-Hispanic, black children have
BPb .10 Rg/dl, in contrast to an overall
average ofabout 4% (5). It may be argued
that the best treatment for the overexposed
children is removal from potential sources
of exposure, but it is unlikely that the
major risk factors, homes containing lead-
based paint, can be corrected in the near
future. From this perspective chelation
becomes an appealing alternative.
However, there are a number of unan-
swered questions regarding the effective-
ness of available chelating agents. There is
currently no conclusive evidence that
reduction ofblood lead levels by chelation
will reverse neurological effects already pre-
sent. Also, historically, the drug of choice
for treatment of lead poisoning is
CaNa2EDTA, which is administered by
infusion, is relatively nonspecific and pro-
motes loss of essential cations. Therefore,
the use of EDTA has been reserved for
instances ofclinical lead toxicity. However,
with the recent availability ofDMSA (suc-
cimer), an orally administered drug, the
enthusiasm for therapy of children with
low-level exposure to lead is growing (6).
But this alternative drug only has FDA
approval for reduction of BPb levels >45
pg/dl.
The adverse effects of excess cadmium
exposure become evident in older adult
populations: renal tubular dysfunction and
hypercalciuria, which is a factor in the
development of osteoporosis (7). Daily
intake of cadmium from food in most
industrialized countries is about 10-50
pg/day; the upper limit recommended by
the U.S. EPA Integrated Risk Information
System is 70 pg day, similar to the permis-
sible weekly intake recommendation ofthe
Joint Food and Agriculture Organi-
zation/World Health Organization Expert
Committee (8). Renal tubular dysfunction
attributable to excess cadmium exposure
affects large populations ofadults in Japan,
The Netherlands, and Belgium (2,9).
Because of the long retention time in soft-
tissue (half-life of30 years), the renal effects
are not reversible within 10 or 15 years or
longer, and may be progressive. It seems
appropriate therefore to look to a chelating
agent to reduce the problem, at least in
severe cases, but none is available at present.
Concern about mercury exposure is
largely from consumption of fish contain-
ing methylmercury, which may be a hazard
to the developing fetus. The EPA and FDA
have monitored fish consumption and
exposures to high-risk populations in the
United States. Again, there is only a small
margin of safety for large groups of chil-
dren, and, as discussed at the conference,
methylmercury is probably not chelatable.
A second exposure to mercury for persons
in the general population is elemental mer-
cury or mercury vapor from dental amal-
gams. Although mercury-containing amal-
gams have been used in dentistry for more
than 100 years without demonstrated
adverse effects, it has how been shown that
mercury in tissues can be related to the
number of mercury-containing dental fill-
ings and that there is a relationship between
numbers ofmercury amalgams and mercury
content of tissues, including the nervous
system, of newborn infants (10). The
chelating agents DMSA and DMPS can
enhance urinary excretion of elemental
mercury, which, in turn, can be related to
the number of mercury-containing dental
fillings. While there is no substantiated
health effect from tissue levels of mercury
attributable to dental amalgams, it is alleged
that a number ofnonspecific, chronic con-
ditions can be ameliorated by removal of
the amalgams or by chelation. None ofthis
has been supported by confirmed peer-
reviewed research, but it has attracted the
public interest in removal of amalgam fill-
ings and chelation therapy for removal of
mercury.
Chelation therapy has long been the
only method for reducing body burdens of
metals resulting from genetic disorders of
metal metabolism such as copper accumula-
tion in Wilson's disease, cystine crystal for-
mation in cystinuria, and removal of tissue
iron in hemochromatosis. For these disor-
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ders the rationale for chelation therapy is
supported to some degree by clinical experi-
ence and there are, at present, no alterna-
tives. However, there is an expanding inter-
est in chelation therapy for the treatment of
degenerative vascular disease due to arte-
riosclerosis. The initial assumption was that
chelation with EDTA worked by chelating
calcium from atherosclerotic plaques and
hence improved blood flow in narrowed
vessels. While this hypothesis has lost favor,
practitoners of chelation therapy believe
that EDTA works by chelating iron and
copper, reducing the generation offree radi-
cals and subsequent lipid peroxidation
(11,12). Literature aimed at the lay reader
and widely available in health food stores
favors chelation therapy for treatment of
"narrowing of the arteries" rather than
established techniques of angioplasty and
bypass surgery (13,14). The effectiveness of
chelation therapy for treatment ofperipher-
al vascular disease is being debated (15);
double-blind, randomized studies do not
support clinical efficacy (16,17). On the
other hand, one might see the appeal ofthe
relatively low cost, noninvasive nature of
this approach. Lay literature provides con-
siderable anecdotal support for effectiveness
and even endorsements bysomephysicians.
All of these interests and needs argue
for increased research effeorts to provide a
better understanding of what chelation
therapy does and does not do and to iden-
tify its risks. In most cases it is not difficult
to demonstrate increased excretion of the
metal, but in few instances has the clinical
efficacy ofthe treatment been demonstrat-
ed with any scientific rigor (18). Although
there may be evidence for the ability of a
particular agent to enhance excretion of a
metal in question, there is a paucity ofevi-
dence that any of the uses of chelation
therapy reverses toxicity at the cellular level
or prevents progression of the pathology
produced by the accumulated metal.
It is apparent that there are serious defi-
ciencies in the understanding and effective-
ness ofchelating agents for the removal of
toxic metals and treatment ofmetal toxici-
ties. There are many reasons for this state
of the science. There has not been suffi-
cient basic research to elucidate the cell
effects and mechanisms of action and
effects ofchelating agents on the biokinet-
ics of toxic metals. Investment in research
in these topics has lagged because of the
view that need for chelation therapy is sec-
ondary to reduction in exposure. Another
major reason is the large costs associated
with drug development for a small and spe-
cialized market. The clinical testing of a
chelating agent involves identification ofan
appropriate cohort, a random double-blind
design that incorporates scientifically credi-
ble measures of clinical outcome, and a
large financial outlay. Added to these diffi-
culties is ethical acceptance of the use of
placebos essential for the conduct ofa dou-
ble-blind study. These considerations do
not foster confidence that the scientifically
desired ideal for these therapies will be
imminent. However, awareness ofthe defi-
ciencies ofknowledge should be reason for
caution not to do harm and not to generate
false expectations.
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